TOPIGEN CEO to Present at Sachs Associates 5th Annual North American Forum
Posted on: Thursday, 9 March 2006, 12:00 CST
TOPIGEN Pharmaceuticals Inc., a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Sachs Associates 5th Annual North American Forum for Investing & Partnering in Biotech & Medtech on March 14, 2006 at 1:55 p.m.
Dr. Wotton's presentation will be held at The Fairmont Copley Plaza Hotel in Boston, MA, and he will be available for one-on-one meetings throughout the conference. The presentation will be accessible live via webcast and for replay at http://www.investorcalendar.com/CEPage.asp?ID=102465.
About TOPIGEN
TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN's pipeline includes small molecule and RNA-based therapeutics. The Company's Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This pioneering approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com.
About Sachs Associates
Sachs Associates is a leading international forum for those interested in investing and partnering in the biotech and medtech industries. Going into its fifth year, the meeting attracts over 500 of the brightest players in the industry and provides prime executive-level networking and deal-making opportunities. The event features executive round-tables, presentations by mid-caps, small-caps, IPO prospects and venture-backed biotech and medtech companies.
For more information about Sachs Associates, please visit www.sachsforum.com
Corporate Contact: G. John Mohr TOPIGEN Pharmaceuticals, Inc. (973) 809-5582 Contact via http://www.marketwire.com/mw/emailprcntct?id=5E0D32C6237ADA79 IR/PR Contact: Donna LaVoie LaVoie Group (781) 596-0200 X103 Contact via http://www.marketwire.com/mw/emailprcntct?id=32AEC0877526B3D1
SOURCE: TOPIGEN Pharmaceuticals
Source: MARKET WIRE
Related Articles
- VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
- VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
- VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
- VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
- VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
- VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
- VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
- VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
- VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
- VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
 |
 |
User Comments (0)
RSS Feeds